Group items tagged

Stock market classes and investment education provided by StockMarketFunding. In this live stock market trading class lesson playlist of four live videos, we'll cover the S&P 500, Dow Jones, VIX, and Apple Computer.

http://www.StockMarketFunding.com Pt 2 Dendreon Huge Drop Down 16.4% In After-Hours Commentary (VIDEO) DNDN Trading Video Dendreon Cancer Drug Dendreon DNDN Update Dendreon's Cancer Vaccine Provenge -- Dendreon Corporation (Nasdaq:DNDN - News) announced that the Centers for Medicare and Medicaid Services (CMS) today initiated a National Coverage Analysis (NCA) of PROVENGE® (sipuleucel-T), an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer (CRPC). PROVENGE is the first in a new therapeutic class known as autologous cellular immunotherapies. In CMS's announcement of the NCA, CMS is requesting public comments on the effects of PROVENGE on health outcomes in patients with prostate cancer. It is not a change in Medicare coverage policy. NCAs do not impact existing coverage decisions, nor do they restrict local Medicare contractors from covering PROVENGE. Therefore, Medicare beneficiaries are still able to access PROVENGE and private payers can also still cover PROVENGE. Dendreon welcomes the opportunity to continue our discussions with CMS about how PROVENGE will be provided to Medicare beneficiaries, particularly given the survival benefit and safety profile of PROVENGE. We plan on continuing to work closely with CMS during this process to ensure patients with advanced prostate cancer have broad access to PROVENGE. Clinical Trial Results Supporting U.S. Food and Drug Administration (FDA) Approval